Filing Details

Accession Number:
0001415889-24-018635
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-01 17:18:21
Reporting Period:
2024-06-27
Accepted Time:
2024-07-01 17:18:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1287098 Maxcyte Inc. MXCT Services-Commercial Physical & Biological Research (8731) 522210438
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1874850 Joseph John Johnston C/O Maxcyte, Inc.
9713 Key West Avenue, Suite 400
Rockville MD 20850
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-06-27 5,044 $1.64 146,994 No 4 M Direct
Common Stock Acquisiton 2024-06-27 4,956 $2.93 151,950 No 4 M Direct
Common Stock Disposition 2024-06-27 10,000 $3.99 141,950 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-06-27 5,044 $0.00 5,044 $1.64
Common Stock Stock Option (right to buy) Disposition 2024-06-27 4,956 $0.00 4,956 $2.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,121 2030-01-20 No 4 M Direct
13,396 2027-07-14 No 4 M Direct
Footnotes
  1. The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.93 to $4.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. This option is fully vested and exercisable.